Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Poly-ICLC in MRP Colon Cancer
NCT02834052Phase 2Completed
- Sponsor
- Asha Nayak
- Start
- Jan 2018
- Primary completion
- Jul 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in colon cancer, sponsored by Asha Nayak. Started Jan 2018; status: completed.
02
Drugs
poly iclc
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02834052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834052.